Examining the Relationship Between Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome in Nondiabetic Subjects

References

• Carey E, Wieckowska A, Carey WD. Nonalcoholic fatty liver disease. Available from: http://www.clevelandclinicmeded/medicalpubs/diseasemanagement/hepatology/nonalcoholic-fatty-liver-disease/.
   Google Scholar
• Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014 Jul 29;349:g4596. doi:10.1136/bmj.g4596. PMID:25239614.
   PubMed Web of Science ®Google Scholar
• Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104:861–7. doi:10.1038/ajg.2009.67. PMID:19293782.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease. 2015;47:181–90. doi:10.1016/j.dld.2014.09.020. PMID:25739820.
   PubMed Web of Science ®Google Scholar
• Kwon Y-M, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with component of MS according to BMI in Korean Adults. Am J Gastroenterol. 2012;107:1852–8. doi:10.1038/ajg.2012.314. PMID:23032980.
   PubMed Web of Science ®Google Scholar
• Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto IY, Wasada T. Prevalence of non-alcoholic fatty live disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141–5. doi:10.1111/j.1464-5491.2005.01582.x. PMID:16108839.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, Cassader M. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with adult treatment panel III criteria in non obese non diabetic subjects. Diabetes Care. 2008;31:562–8. doi:10.2337/dc07-1526. PMID:18056890.
   PubMed Web of Science ®Google Scholar
• Appel SJ, Harrell JS, Davenport ML. Central obesity, the metabolic syndrome and plasminogen activator inhibitor-1 in young adults. J AM Acad Nurse Pract. 2005;17:535–41. doi:10.1111/j.1745-7599.2005.00083.x. PMID:16293162.
   PubMedGoogle Scholar
• Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5. doi:10.1016/S0002-9343(99)00271-5. PMID:10569299.
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, Camilo ME, Baptista A, Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–8. doi:10.1016/S0261-5614(99)80015-6. PMID:10634920.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–10. doi:10.1016/S2213-8587(14)70032-4. PMID:24731669.
   PubMed Web of Science ®Google Scholar
• Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol. 2013;28:664–70. doi:10.1111/jgh.12106. PMID:23286209.
   PubMed Web of Science ®Google Scholar
• Xia MF, Yan HM, Lin HD, Bian H, Pan BS, Yao XZ, Li RK, Zeng MS, Gao X. Elevation of liver enzymes within the normal limits and metabolic syndrome. Clin Exp Pharmacol Physiol. 2011;38:373–9. doi:10.1111/j.1440-1681.2011.05519.x. PMID:21418268.
   PubMed Web of Science ®Google Scholar
• Preuss HG, Mrvichin N, Bagchi D, Preuss J, Perricone N, Kaats GR. Importance of fasting blood glucose in screening/tracking over-all health. The Orig Intern. 2016;23:13–20.
   Google Scholar
• Preuss HG, Mrvichin N, Bagchi D, Preuss J, Perricone N, Kaats GR. Fasting circulating glucose levels in the non-diabetic range correlate appropriately with many components of the metabolic syndrome. The Orig Intern. 2016;23:78–89.
   Google Scholar
• Preuss HG, Mrvichin N, Bagchi D, Preuss J, Perricone N, Kaats GR. General lack of correlations between individual age and signs of the metabolic syndrome in those with non-diabetic fasting glucose. J Am Coll Nutr. 2017;36:556–64. doi:10.1080/07315724.2017.1322545. PMID:28895791.
   PubMed Web of Science ®Google Scholar
• Preuss HG, Kaats GR, Mrvichin N, Bagchi D. Longitudinal examination of links between risk factors for the metabolic syndrome and both age and fasting glucose levels in non-diabetic subjects. J Amer Coll Nutr. 2018; 13:1–6. doi:10.1080/07315724.2017.1413962. [Epub ahead of print]
   Google Scholar
• Preuss HG, Kaats GR. Examining possible causes for age-related blood pressure elevations in 107 females volunteering for a weight loss study. The Orig Intern. 2011;18:92–95.
   Google Scholar
• Hamaguchi M, Takada N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18:1508–16. doi:10.3748/wjg.v18.i13.1508. PMID:22509083.
   PubMed Web of Science ®Google Scholar
• Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N. Insulin sensitizers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess. 2011;15:1–110. doi:10.3310/hta15380. PMID:22059955.
   PubMed Web of Science ®Google Scholar
• Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19:597–601. doi:10.4103/2230-8210.163172. PMID:26425466.
   PubMedGoogle Scholar
• Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: is liver biopsy obsolete? Cleve Clin J Med. 2010;77:519–27. doi:10.3949/ccjm.77a.09138. PMID:20682514.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. Am J Gastroenterol. 2006;101:76–82.
   Google Scholar
• Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatol. 2006;43:1145–51. doi:10.1002/hep.21171.
   PubMed Web of Science ®Google Scholar
• Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7. doi:10.1111/j.1572-0241.2003.07486.x. PMID:12809815.
   PubMed Web of Science ®Google Scholar
• Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman MI, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–92. doi:10.1053/jhep.2003.50229. PMID:12774006.
   PubMed Web of Science ®Google Scholar
• Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Phys. 2005;15:1105–10.
   Google Scholar
• Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am Coll Gastroenterol. 1999;94:1018–22. doi:10.1111/j.1572-0241.1999.01006.x.
   PubMed Web of Science ®Google Scholar
• Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int. 2007;27:694–9. doi:10.1111/j.1478-3231.2007.01471.x. PMID:17498256.
   PubMed Web of Science ®Google Scholar
• Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffman U, Fox CS. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arteriosclero Thromb Vasc Biol. 2013;33:139–46. doi:10.1161/ATVBAHA.112.300075.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. RISC Investigators: fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537–44. doi:10.1002/hep.22845. PMID:19291789.
   PubMed Web of Science ®Google Scholar
• Nyblom H, Bjornsson E, Simren M, Aldenborg F, Almer S, Olsson R. The AST/ALT ratio as an indicator of cirrhosis I patients with PBC. Liver Int. 2006;26:840–5. doi:10.1111/j.1478-3231.2006.01304.x. PMID:16911467.
   PubMed Web of Science ®Google Scholar
• Mofrad PS, Sanyal AJ. Commentary. Nonalcoholic fatty liver disease. New York, NY: Medscape; Apr 16, 2003.
   Google Scholar
• Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Fortani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50. doi:10.2337/diabetes.50.8.1844. PMID:11473047.
   PubMed Web of Science ®Google Scholar
• Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liv Dis. 2010;42:320–30. doi:10.1016/j.dld.2010.01.016.
   Web of Science ®Google Scholar
• Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Ramagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218–24. doi:10.1001/archinte.163.2.218. PMID:12546613.
   PubMedGoogle Scholar
• Van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisolm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008;48:449–57. doi:10.1002/hep.22350. PMID:18627003.
   PubMed Web of Science ®Google Scholar
• Yang KC, Hung H-F, Lu C-W, Chang H-H, Lee L-T, Huang K-C. Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci Reports. 6:27034. doi:10.1038/srep27034.
   PubMed Web of Science ®Google Scholar
• Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic liver disease in adults: a systematic review. J Hepatology. 2012;56:255–66. doi:10.1016/j.jhep.2011.06.010.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–95. doi:10.1210/jc.2012-3093. PMID:23293330.
   PubMed Web of Science ®Google Scholar
• Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA. 2006;103:18273–4. doi:10.1073/pnas.0608537103. PMID:17114290.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liv Dis. 2007;11:105–17. doi:10.1016/j.cld.2007.02.013.
   PubMedGoogle Scholar
• Fournier AM, Gadia MT, Kubrusly DB, Skyler JS, Sosenko JM. Blood pressure, insulin, and glycemia in nondiabetic subjects. Amer J Med. 1986;80:861–4.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94. doi:10.2337/diacare.14.3.173. PMID:2044434.
   PubMed Web of Science ®Google Scholar
• Preuss HG, Gondal JA, Bustos E, Bushehri N, Lieberman S, Bryden NA, Polansky MM, Anderson RA. Effect of chromium and guar on sugar-induced hypertension in rats. Clin Neph. 1995;44:170–7.
   PubMed Web of Science ®Google Scholar
• Barnard RJ, Roberts CK, Varon SM, Berger JJ. Diet-induced insulin resistance precedes other aspects of the metabolic syndrome. J Appl Physiol. 1998;84:1311–5. doi:10.1152/jappl.1998.84.4.1311. PMID:9516198.
   PubMed Web of Science ®Google Scholar
• Reaven GM. The individual components of the metabolic syndrome: is there a raison d'etre? J Amer Coll Nutr. 2007;26:191–5. doi:10.1080/07315724.2007.10719601.
   PubMed Web of Science ®Google Scholar
• Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non alcoholic liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum enzymes. BMC Med. 2011 July 12;9:85. doi:10.1186/1741-7015-9-85. PMID:21749681.
   PubMed Web of Science ®Google Scholar
• Dasarathy J, Periyalwar P, Allampati S, Bhinder V, Hawkins C, Brandt P, Khiyami A, McCullough AJ, Dasarathy S. Hypovitaminosis D is associated with increased body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:118–27. doi:10.1111/liv.12312. PMID:23738963.
   PubMed Web of Science ®Google Scholar
• Nelson JE, Roth CL, Wilson LA, Yates KP, Aquizerat B, Morgan-Stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV. Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: possible role for MAPK and NF-kB? Am J Gastroenterol. 2016;111:852–63. doi:10.1038/ajg.2016.51. PMID:27002799.
   PubMed Web of Science ®Google Scholar
• Kim H-S, Rotundo L, Kothari N, Kim S-H, Pyrsopoulos N. Vitamin D is associated with severity and mortality of non-alcoholic fatty liver disease: a US population-based study. J Clin Transl Hepatol. 2017;5:185–92. PMID:28936398.
   PubMedGoogle Scholar
• Strange RC, Shipman KE, Ramachandran S. Metabolic syndrome: a review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes. 2015;6:896–911. doi:10.4239/wjd.v6.i7.896. PMID:26185598.
   PubMed Web of Science ®Google Scholar
• Preuss HG, Kaats GR. Dietary approaches in weight management: analyzing clinical studies. J Amer Coll Nutr. 2008;27:599. ( abstract).
   Google Scholar
• Preuss HG, Echard B, Bagchi D, Perricone NV. Anti-aging nutraceuticals. In: Klatz R, Goldman R, editors. Antiaging therapeutics. Chicago, Illinois: American Academy of Anti-Aging Medicine; 2008. p. 219–24.
   Google Scholar
• Preuss HG, Clouatre D. Potential of diet and dietary supplementation to ameliorate the chronic clinical perturbations of the metabolic syndrome. In: Sinatra S, Houston M, editors. Nutritional and integrative strategies in cardiovascular medicine. Boca Raton (Florida): CRC Press; 2015. p. 148–78.
   Google Scholar
• Preuss HG. The bitter sweet. Purcell, Oklahoma: Marcell Publishing; 2017. p. 1–116.
   Google Scholar
• Wainwright P, Byrne CD. Bidirectional relationships and disconnects between NAFLD and features of the metabolic syndrome. Int J Molec Sci. 2016 Mar 11;17(3):367. doi:10.3390/ijms17030367.
   PubMed Web of Science ®Google Scholar